January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
April 2020 in “Rheumatology” Rituximab therapy successfully treated a patient's complete body hair loss and was effective for six years.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
5 citations
,
February 2025 in “Pediatric Dermatology”
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
3 citations
,
September 2025 in “Frontiers in Immunology” JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
3 citations
,
June 2025 in “Archives of Dermatological Research” Stopping TNFα inhibitors can help children regrow hair lost due to the medication.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
7 citations
,
May 2021 in “EBioMedicine” Increased methylation of the Filip1l gene may contribute to aggressive skin cancer.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
1 citations
,
November 2025 in “Expert Review of Clinical Immunology”
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
3 citations
,
November 2023 in “The Journal of Dermatology” 8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
1 citations
,
January 2025 in “Dermatologic Therapy” Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.
November 2025 in “Journal of Investigative Dermatology”